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Abstract
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs
during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules
PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer
(NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are now FDA
approved for use in certain patients who have failed or progressed on platinum-based or targeted therapies while
agents targeting PD-L1, atezolizumab and durvalumab, are approaching the final stages of clinical testing. Despite
impressive treatment outcomes in a subset of patients who receive these immune therapies, many patients with
NSCLC fail to respond to anti-PD-1/PD-L1 and the identification of a biomarker to select these patients remains
highly sought after. In this review, we discuss the recent clinical trial results of pembrolizumab, nivolumab, and
atezolizumab for NSCLC, and the significance of companion diagnostic testing for tumor PD-L1 expression.
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Background
Non-small cell lung cancer (NSCLC) is by far the leading
cause of cancer related mortality in the US and worldwide
[1, 2]. It is frequently diagnosed in the metastatic or
unresectable setting, while those patients that do undergo
potentially curative surgery will frequently relapse [3].
Despite advances in cancer treatment and survival over
the last 30 years, improvements in survival for lung cancer
patients have been comparatively modest, prompting re-
search into new modalities of therapy for lung cancer [2].
The introduction of molecularly targeted agents to
NSCLC therapy was a major breakthrough, though these
drugs benefit only a small proportion of patients (mostly
never smokers) who harbor activating genetic alterations
including EGFR, ALK, and ROS1 [4].
NSCLC was not traditionally considered to be an im-
munotherapy responsive tumor type when the earliest
clinical trials employed interleukin-2, vaccines, and in-
terferons [5]. More recently, major treatment responses
have been observed with the use of immune checkpoint
inhibitors. Immune checkpoints are proteins on the
surface of lymphocytes and other immune cells, most
notably on cytotoxic T-cells. When bound to their spe-
cific ligand, often another surface bound protein on a
neighboring cell, they can transmit stimulatory or inhibi-
tory signals to activate or dampen the cellular adaptive
immune response [6]. Mounting evidence suggests that
the predominant mechanism by which NSCLC evades
detection and elimination by the immune system is by
exploiting one such inhibitory pathway through the ex-
pression of programmed death ligand 1 (PD-L1, B7-H1)
[7]. PD-L1 then binds to its receptor, programmed cell
death protein 1 (PD-1), on surveilling lymphocytes and
initiates a signaling cascade which leads to lymphocyte
exhaustion, a state of impaired function [8].
The most successful immune checkpoint inhibitors so
far are monoclonal antibodies which bind to either PD-1
or PD-L1 and prevent their interaction at the tumor-
immune interface. The depth and durability of responses
in NSCLC have revolutionized the conceptual approach
to lung cancer treatment. Still, fewer than a quarter to
half of patients, even in highly selected cohorts, have
experienced a clinical benefit while on anti-PD-1 or
anti-PD-L1 therapies. In this review, we will describe the
recent data leading to the FDA approvals of nivolumab
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(Opdivo, approved in December 2014 and March 2015
for non-squamous and squamous NSCLC in the 2nd line
setting) and pembrolizumab (Keytruda, approved in
October 2015 for PD-L1 positive NSCLC also in the 2nd
line setting). We will also explore the ongoing effort and
challenges to identify a PD-L1 assay that can select pa-
tients who will benefit from these drugs.
Nivolumab
Four large clinical trials have reported on the use of
nivolumab for NSCLC, however some of the most im-
portant observations came from the initial phase I trial
published in 2010. That trial enrolled patients with di-
verse malignancies, including six patients with NSCLC,
but only a small number of responses were seen [9]. In
several patients, pre- and post- treatment biopsies were
tested for PD-L1 expression by immunohistochemistry
(IHC) using a non-commercial antibody (5H1), with an
indication that PD-L1 expression correlated with re-
sponse. Post-treatment tumor lesions were infiltrated
with CD8+ but not CD4+ lymphocytes. In the peripheral
blood, T-cell markers, but not B- or NK-cell markers,
were noted to drop by day 2 of treatment, but then in-
creased substantially and remained elevated for about
30 days. These findings suggested that the effects of
nivolumab treatment were rapid and resulted in a major
redistribution of existing lymphocytes, followed by a
prolonged period of immune activation which correlated
with the anti-tumor response [9].
A much larger phase I study was reported in 2012,
which included 122 evaluable patients with heavily pre-
treated NSCLC [10]. Treatment was well tolerated, though
fatigue was common and seen in approximately 40 % of
patients who experienced a treatment related adverse
event (AE). Serious AEs occurred in 11 % of all patients
including two deaths in the NSCLC cohort due to pneu-
monitis. These early deaths may have been preventable
with earlier intervention, as the autoimmune toxicities of
the drugs were still poorly understood at the time. Still,
just 5 % of patients discontinued treatment for toxicity
reasons and some patients with immune-related endocri-
nopathies, colon and liver toxicities tolerated treatment
re-challenge. Clinical activity was evident, with 14 re-
sponses (18 %) seen in the NSCLC group, and 3 mg/kg
(every 2 weeks) was identified as the optimal dose. Of 61
pre-treatment tumors in the study tested for PD-L1 using
the same 5H1 antibody, 36 % of positive patients but none
of the negative patients responded [10].
Long-term follow-up is now available from the phase I
expansion, totaling 129 NSCLC patients with a median
follow-up of 39 months (up to 66 months) as of 2015 [11].
All patients had failed at least one chemotherapy regimen,
54 % had failed three or more. The overall response rate
was 17 % (and was 22 % at the doses considered therapeutic:
3 mg/kg and 10 mg/kg) with most responses lasting over a
year and the longest ongoing at 3 years. A further 5 % of
patients experienced an initial disease pseudo-progression
or a mixed response, both phenomena consistent with an
immune pattern of response that is not captured by
standard Response Evaluation Criteria in Solid Tumors
(RECIST) criteria [12]. Responses were seen regardless of
subgroups: squamous and non-squamous, EGFR and
KRAS mutated, PD-L1 positive and negative, while those
with a smoking history more than 5 pack-years did much
better (overall response rate [ORR] 30 % vs 0 for <5 pack-
years). The median overall survival (OS) was 9.9 months,
and at 3 years 27 % of patients were still alive and 9 %
progression-free. Only six treatment related grade 3 or 4
AEs were reported including three pneumonitis, one col-
itis, and one hepatitis. One reassuring observation was
that half of the 18 patients who discontinued therapy for
toxicity had a continued response lasting > 9 months, sug-
gesting that early re-challenging with anti-PD-1 therapies
after toxicity may not be necessary in some patients who
have responded.
Three phase II and III clinical trials were initiated to
evaluate squamous and non-squamous tumors inde-
pendently. For squamous NSCLC, a phase II single arm
study enrolled 117 heavily pre-treated patients with
unresectable disease, the vast majority of whom were
prior or current smokers [13]. The best ORR was
14.5 %, with one patient having a complete response by
investigator assessment. Treatment toxicity was higher
in this population, 27 % of patients required a dose delay
and 17 % experienced a treatment related grade 3 or 4
AE, including four patients with pneumonitis and three
with colitis. Low grade gastrointestinal (GI) toxicity and
fatigue were also common but manageable.
CHECKMATE 017 and CHECKMATE 057 were
parallel, randomized controlled phase III trials for ad-
vanced, platinum-refractory squamous and non-squamous
NSCLC, respectively, and are summarized in Table 1. In
CHECKMATE 017 [14], nivolumab bested docetaxel
(75 mg/m2 every 3 weeks) in terms of the primary end-
point OS (median 9.2 vs 6.0 months; hazard ratio [HR]
0.59, p < 0.001) and ORR (20 % vs 9 %; odds ratio [OR]
2.6, p = 0.008). It is important to mention that 34 % of
patients had previously received paclitaxel, though this is
unlikely to fully account for the differential activities.
Consistent with the earlier studies, 9 patients on
nivolumab (6.5 %) experienced a delayed response follow-
ing an initial pseudo-progression. Nivolumab was much
better tolerated than docetaxel, with grade 3 or 4 AEs in
just 7 % of nivolumab treated patients vs 55 % for doce-
taxel. The most common immune-related toxicities were
hypothyroidism, colitis, pneumonitis, nephritis, and rash,
each occurring at a rate of about 4–8 % (all grades), and
there were no immune-related deaths.
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CHECKMATE 057 enrolled exclusively patients with
non-squamous NSCLC and patients were randomized to
docetaxel or nivolumab [15]. Again, all study outcomes
favored nivolumab including OS (12.2 vs 9.4 months),
ORR (19 % vs 12 %), and safety (grade 3 or 4 treatment
related AEs in 10 % vs 54 %) with similar rates of
immune-related toxicities to CHECKMATE 017. In the
subgroup analysis, no survival advantage was observed
for never smokers nor for those with activating EGFR
mutations. Patients receiving third line therapy or with
brain metastases also did not benefit from nivolumab
over docetaxel, but this was probably more reflective of
an underlying aggressive or advanced disease variant
than of a differential treatment effect.
Pembrolizumab
Two clinical trials have studied pembrolizumab in pa-
tients with advanced NSCLC. KEYNOTE 001 was a
large phase I trial with a NSCLC expansion cohort that
enrolled 495 patients who were treated with pembrolizu-
mab 2 mg/kg or 10 mg/kg every 2–3 weeks [16]. The
trial included 101 patients who had never received sys-
temic therapy. Objective responses were seen in 19.4 %
of patients, including 24.8 % of chemotherapy naïve pa-
tients, while another 21.8 % of patients achieved stable
disease. Treatment was effective at all tested doses and
schedules, thus an every 3 week schedule was chosen for
the phase III study. Responses were more common in
former or current smokers compared to non-smokers
(22.5 % vs 10.3 %). Treatment-related adverse events were
common (70.9 %), and 9.5 % of patients had grade 3–5
toxicities. Immune-related toxicities like hypothyroidism
(6.9 %) and pneumonitis (3.6 %) were mostly manageable
though one patient died of severe pneumonitis. Fresh
tumor biopsies were required for PD-L1 staining by IHC,
and observed response rates were higher with increasing
percentages of tumor PD-L1 expression (Fig. 1). Re-
sponses were durable, lasting a median of 12.5 months
(range 1–23.3 months). Median OS was 9.3 months for
previously treated patients and 16.2 months for chemo-
therapy naïve patients.
KEYNOTE 010 was a randomized phase III trial analo-
gous to CHECKMATE 017 and 057, comparing pembroli-
zumab at two doses, 2 mg/kg and 10 mg/kg every
3 weeks, to docetaxel in 1034 patients [17]. The study en-
rolled only patients with at least 1 % PD-L1 positive stain-
ing, with the last 593 patients stratified by PD-L1
positivity using a 50 % cutoff. Patients treated with either
dose of pembrolizumab had a higher median OS than with
docetaxel (10 mg/kg: 12.7 months vs 8.5 months; HR 0.61,
p < 0.0001; 2 mg/kg: 10.4 months, HR 0.71, p = 0.0008).
There was a non-significant trend toward longer survival
in the 10 mg/kg cohort compared with the 2 mg/kg
cohort. When stratified by PD-L1 positivity, defined as a
proportion score (PS) ≥50 % staining of the tumor, the
survival benefits were more pronounced (HR 0.50 and
0.54 for 10 mg/kg and 2 mg/kg cohorts, respectively), with
median survivals of 17.3 and 14.9 months. In the sub-
group analysis, both squamous and non-squamous hist-
ology favored pembrolizumab treatment, consistent with
Table 1 Response rates to anti-PD-1 and overall survival in NSCLC by study




Gettinger et al. [11]a All Nivolumab 3 mg/kg q2wks 37 24.3 17 14.9
Nivolumab 10 mg/kg q2wks 59 20.3 19.1 9.2
Rizvi et al. [13]
(CHECKMATE 063)
Squamous Nivolumab 3 mg/kg q2wks 117 14.5 Not reached 8.2
Brahmer et al. [14]
(CHECKMATE 017)
Squamous Nivolumab 3 mg/kg q2wks 135 20 Not reached 9.2
Docetaxel 75 mg/m2 q3wks 137 9 8.4 6
Borghaei et al. [15]
(CHECKMATE 057)
Non-squamous Nivolumab 3 mg/kg q2wks 292 19 17.2 12.2
Docetaxel 75 mg/m2 q3wks 290 12 5.6 9.4
Bauer et al. [55] All Nivolumab 3 mg/kg q 2wks 51 13.7 Not reported Not reported
Pembrolizumab
Garon et al. [16]
(KEYNOTE 001)
All Pembrolizumab 2 mg/kg q3wks 6 33.3 12.5 9.3 (prior therapy)
Pembrolizumab 10 mg/kg q3wks 287 19.2 16.2 (no prior therapy)
Pembrolizumab 10 mg/kg q2wks 202 19.3
Herbst et al. [17]
(KEYNOTE 010)
All Pembrolizumab 2 mg/kg q3wks 344 18 Not reached 10.4
Pembrolizumab 10 mg/kg q3wks 346 18.5 Not reached 12.7
Docetaxel 75 mg/m2 q3wks 343 9.3 6 8.5
aCohorts receiving doses lower than 3 mg/kg were omitted from the table due to low response rates
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results from the nivolumab clinical trials. Similarly, EGFR
mutated tumors seemed to have no survival advantage
with pembrolizumab over docetaxel, though the number
of patients (n = 86) was small. Pembrolizumab was more
tolerable than docetaxel, with fewer grade 3–5 AEs (14 %
vs 35 %) and fewer drug discontinuations (4.7 % vs 10 %).
There were six (0.9 %) pembrolizumab-attributed deaths,
three due to pneumonitis, two pneumonia, and one myo-
cardial infarction, and five (1.6 %) docetaxel-attributed
deaths. Based on the unprecedented survival achieved in
the PD-L1+ population, the FDA approved pembrolizu-
mab for second line therapy but only for tumors with a
PD-L1 PS ≥50 %.
Companion PD-L1 testing
Nivolumab/Dako IHC 28–8 pharmDx
In the multi-tumor phase I trial, a non-commercial
anti-PD-L1 murine monoclonal antibody (5H1) was
used to measure PD-L1 expression by IHC in tumor
biopsies [9, 18]. Each stained tumor section was scored
by the degree of membranous staining on tumor cells,
with a minimum requirement of 100 evaluable tumor
cells. The “positive” threshold was set at 5 % of cells based
on test performance characteristics. There appeared to be
differential response rates, with 36 % of PD-L1 positive vs 0
PD-L1 negative tumors experiencing a treatment response
[10]. The antibody used in this assay was later abandoned
in favor of commercial assay developed by Dako using
clone 28–8, a rabbit anti-human PD-L1 (see Table 2). Two
of the four subsequent publications using this assay in
NSCLC have demonstrated an apparent value for this PD-
L1 test. In the smaller CHECKMATE 063, a single arm
study in squamous NSCLC, 24 % of PD-L1 positive patients
(n = 25) and 14 % of negative patients (n = 51) had an ob-
jective response. In CHECKMATE 057, PD-L1 positivity at
≥5 % strongly correlated with objective response (34 % vs
14 % for PD-L1 negative) as well as predicted an OS benefit
compared with docetaxel (PD-L1+ HR 0.43 vs PD-L1- HR
1.01; p < 0.001) [15]. Meanwhile, in CHECKMATE 017,
PD-L1 positivity at any cutoff was not significantly prog-
nostic nor predictive of benefit in squamous histology [14].
However, the power of this study was limited by a smaller
sample size than CHECKMATE 057, and a closer inspec-
tion of the study outcomes suggests not only trends toward
improved ORR and OS for PD-L1 positive patients, but
also nearly double the number of patients in the “tail” of
the PD-L1 positive progression-free survival (PFS) curve
suggesting a higher likelihood of long term benefit. Most
importantly, in all studies a significant proportion of PD-L1
negative patients clearly benefitted from treatment with
nivolumab. Similar observations have been made in the
melanoma clinical trials using the same assay (see Table 3).
As a consequence, the FDA label for nivolumab did not
specify any threshold PD-L1 positivity, in fact it did not re-
quire PD-L1 testing at all and the Dako 28–8 assay was la-
belled as “complementary.”
Pembrolizumab/Dako IHC 22C3 pharmDx
The pembrolizumab companion PD-L1 assay, also commer-
cially available from Dako, uses a distinct antibody clone,
Fig. 1 PD-L1 proportion scores and their relationship to objective response rates to pembrolizumab in KEYNOTE 001 and KEYNOTE 010
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22C3 (mouse anti-human PD-L1). This automated assay is
performed on formalin-fixed, paraffin-embedded (FFPE) tis-
sue using similar conditions for heat-based antigen retrieval
and staining as the 28–8 assay. After staining is completed,
the percentage of membranous PD-L1 staining of neoplastic
or intercalating immune cells is counted manually and the
PS is reported as a percentage (see Table 2).
In KEYNOTE 001 for NSCLC, it was evident early in
the trial that increasing efficacy correlated with PD-L1
positivity by this IHC assay [19]. Following enrollment
of 51 patients, the study was modified to include only
patients with at least 1 % PD-L1 positivity [16]. The in-
vestigators also noted that when archival tissue over
6 months old was used for testing, the PD-L1 protein
had deteriorated resulting in unreliable staining. To
identify an optimal cutoff for PD-L1 positivity, a training
cohort of 61 tumors was stained for PD-L1 and a thresh-
old PS ≥ 50 % was established as the positive threshold.
Among the total screened patients, the prevalence of
PD-L1 PS ≥50 % was 23.2 %, while another 37.6 % had a
PS between 1 and 49 %. Patients with activating EGFR
mutations or ALK rearrangement were equally as likely
to have high PD-L1 expression as non-mutated tumors,
though the total patients with these mutations was low.
At the time of analysis, both PFS and OS were consid-
erably longer for the group with a PD-L1 PS ≥50 % (~40
and 65 % at 1 year, respectively), while PFS and OS were
similar for the groups with a PS ≤1 % or 1–49 % (~10
and 40 % at 1 year). The duration of response, however,
was no different between groups, suggesting that even
patients with PD-L1 “negative” tumors could attain a
durable, meaningful benefit albeit at a much lower fre-
quency than the PD-L1 “positive” tumors.
In KEYNOTE 010 the same assay was used with a
threshold for PD-L1 high (PS ≥50 %), intermediate (PS 1–
49 %), or low (PS ≤1 %) tumors, roughly a third of patients
fell into each category and those with PS ≤1 % were
excluded from the trial. As noted earlier in this review,
patients with a higher PS were much more likely to have an
objective response to pembrolizumab (30 %), however
responses were still observed in 10 % of those with a PS 1–
49 % and the OS subgroup analysis still favored pembroli-
zumab over docetaxel (HR 0.76, 95 % CI 0.60–0.96). Inter-
estingly, this group with intermediate PD-L1 expression did
not have a PFS advantage over docetaxel (HR 1.04), a
potential indicator that atypical immunologic anti-tumor
responses are more common in this subset.
Other antibodies in development
Several anti-PD-1 (pidilizumab/CT-011, REGN2810) and
anti-PD-L1 antibodies (durvalumab/MEDI4736, atezolizu-
mab/MPDL3280A, avelumab/MSB0010718C, BMS-936559)
are in various stages of clinical development for NSCLC and
other cancers. Like nivolumab and pembrolizumab, these
agents are designed to block the interaction of PD-1 with
PD-L1 and most have been modified to have no Fc-
mediated antibody dependent cellular cytotoxicity.
A phase II randomized trial (POPLAR) with atezolizu-
mab was recently published. In this trial, 287 patients
with previously treated advanced or metastatic NSCLC
were randomized 1:1 to docetaxel or atezolizumab
(given at a flat dose of 1200 mg IV every 3 weeks) [20].
Overall survival, the primary endpoint, was improved in
the atezolizumab arm by nearly 3 months (median OS
12.6 months vs 9.7 months; HR 0.73, p = 0.04), while
safety was similar to other anti-PD-1 agents (11 % with
treatment related grade 3 or 4 AEs). Responses lasted a
median of 14.3 months (vs 7.2 months for docetaxel),
while neither the ORR nor PFS were higher in the
atezolizumab arm, confirming that traditional radio-
graphic criteria are imprecise measures of benefit from
immunotherapy.
Table 2 Companion PD-L1 Assays in Development for PD-1/PD-L1 Inhibitors
Drug Drug target Companion antibody clone Developer Definition of positive test
Nivolumab PD-1 28-8 Dako ≥5 % membranous staining of tumor cells
(minimum 100 cells evaluated)
Bristol-Meyers Squibb
Pembrolizumab PD-1 22C3 Dako ≥1%a membranous staining of tumor cells
or immune cells that are intercalating or at
the tumor interfaceMerck
Atezolizumab (MPDL3280A) PD-L1 SP142 Ventana Each specimen assigned a score based on
both tumor and immune cell PD-L1:
Genentech/Roche
TC3/IC3 PD-L1≥ 50 %
TC2/IC2 PD-L1 5-49 %
TC1/IC1 PD-L1 1-4 %
TC0/IC0 PD-L1 < 1 %
Durvalumab (MEDI4736) PD-L1 SP263 Ventana ≥25 % membranous staining of tumor cells
MedImmune/AstraZeneca
aThe FDA indication in NSCLC for pembrolizumab requires PS ≥50 %
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Table 3 Response rates to anti-PD-1/PD-L1 antibodies in NSCLC and selected malignancies according to PD-L1 positivity
Study Antibody Tumor type PD-L1 cutoff N Response (%)
Nivolumab
Topalian et al. [10] 5H1 Multiple ≥5 % 25 36
<5 % 17 0
Gettinger et al. [11] 28-8 NSCLC ≥5 % 33 15
<5 % 35 14
Rizvi et al. [13] 28-8 Squamous NSCLC ≥5 % 25 24
<5 % 51 14
Brahmer et al. [14] 28-8 Squamous NSCLC ≥5 % 42 21
<5 % 75 15
Borghaei et al. [15] 28-8 Non-squamous NSCLC ≥5 % 95 34
<5 % 136 14
Hodi et al. [56] 28-8 Melanoma ≥5 % 18 44
<5 % 23 13
Robert et al. [57] 28-8 Melanoma ≥5 % 74 53
<5 % or indet 136 33
Weber et al. [58] 28-8 Melanoma (ipilimumab refractory) ≥5 % 55 44
<5 % 64 20
Larkin et al. [59] 28-8 Melanoma ≥5 % 80 58
<5 % 208 41
Pembrolizumab
Garon et al. [16] 22C3 NSCLC ≥50 % 119 41
<50 % 237 13
Herbst et al. [17] 22C3 NSCLC ≥50 % 290 30
1–49 % 400 10
Kefford et al. [60] 22C3 Melanoma ≥1 % 55 51
<1 % 16 6
Puzanov et al. [61] 22C3 Melanoma (ipilimumab refractory) ≥1 % 193 26
<1 % 93 15
Robert et al. [62] 22C3 Melanoma ≥1 % 896 NR (PFS HR 0.53)
<1 % 197 NR (PFS HR 0.67–0.76)
Atezolizumab (MPDL3280A)
Spigel et al. [63] SP142 NSCLC TC or IC ≥50 % 53 26
TC or IC 5–49 % 84 14
Spira et al. [20, 64] SP142 NSCLC TC or IC ≥50 % 24 38
TC or IC 1–49 % 69 12
TC and IC <1 % 51 8
Besse et al. [65] SP142 NSCLC TC or IC ≥50 % 302 26
TC or IC 5–49 % 357 10
Powles et al. [66] SP142 Urothelial TC or IC ≥5 % 30 43
TC and IC <5 % 35 11
Rosenberg et al. [67] SP142 Urothelial TC or IC ≥5 % 100 26
TC and IC 1–5 % 107 11
TC and IC <1 % 103 8
Herbst et al. [21] SP142 Multiple TC or IC ≥50 % 33 46
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Importantly, enrollment was stratified by PD-L1 ex-
pression using a novel IHC assay (Ventana SP142,
Table 3) in which PD-L1 positivity was categorized ac-
cording to the expressing cell type (tumor cell [TC] or
immune cell [IC]) and then scored along a gradient
(<1 % [TC0 or IC0], 1–4 % [TC1 or IC1], 5–49 % [TC2
or IC2], and ≥50 % (TC3 or IC3]). Treatment with ate-
zolizumab was favored in all but the least PD-L1 positive
tumors (TC0 and IC0; HR 1.04). Other biomarkers were
explored, including IHC expression of PD-L2, B7.1 (an
alternative receptor for PD-L1), and PD-1 as well as an
expression panel of T-effector and interferon-γ associ-
ated genes, all of which were predictive of a survival
benefit from atezolizumab.
PD-L1 testing limitations
As outlined, considerable effort has been invested to de-
velop quantifiable, reproducible PD-L1 assays to predict
which patients should receive immune checkpoint inhib-
itors. The commercial complementary PD-L1 diagnostic
test for nivolumab (Dako 28–8 pharmDx) and compan-
ion test for pembrolizumab (Dako 22C3 pharmDx) are
now FDA approved for use in NSCLC, while the
complementary test for atezolizumab (Ventana SP142) is
approved for urothelial carcinoma. The performance
characteristics of the companion tests for atezolizumab
and durvalumab (Ventana SP263) are still being assessed
in NSCLC (Table 3). It is expected that each of these
drugs and assays will ultimately become available to
practicing oncologists.
Still, the performance of these IHC-based assays has
been somewhat disappointing, as most “positive” cutoffs
would exclude a considerable number of responders in
the range of 10–20 %. Therein lies the first drawback to
PD-L1 testing, which is, how is PD-L1 “positivity” de-
fined? PD-L1 can be expressed by both tumor and in-
flammatory cells within the tumor microenvironment,
though the relative importance of either is unclear [21].
There is no consensus to the relevance of geographic pat-
terns of expression (eg. proximity of PD-L1 to immune in-
filtrating lymphocytes, membranous vs cytoplasmic) and
quantitative cutoffs have been variably described. Based
on the findings in KEYNOTE 001 (Fig. 1), it may make
more sense to consider PD-L1 expression as a continuous
measures rather than a binary “positive” or “negative.”
Along these lines, currently published tissue studies have
found PD-L1 positivity to indicate favorable, unfavorable,
or have no relationship to prognosis, as well as variable
correlations with histology and mutation status in NSCLC
and other tumor types [22–32].
Technical aspects of the assays are also an important
source of inconsistency. This topic was reviewed in
detail recently [33, 34]. The quality of commercially
available antibodies is a major concern with considerable
variability in staining intensity and patterns found be-
tween antibodies [23]. Until recently, no information
was available to compare the companion diagnostics in
development by Dako and Ventana (Table 2). Assay vari-
ables pertaining to tissue fixation, storage, and antigen
retrieval can result in PD-L1 degradation and these vari-
ables are not standardized. Importantly, the KEYNOTE
010 trial confirmed that archival tissue (as opposed to
fresh tissue) can be used for PD-L1 staining and this has
been observed in other trials [17, 35]. But the lack of
methodologic transparency and standardization across
platforms may partially explain why PD-L1 positivity has
had such widely varying clinical significance, not only in
NSCLC but also in other tumor types. Table 3 lists re-
sponse rates for anti-PD-1 and anti-PD-L1 treatments
according to companion PD-L1 “positivity” in NSCLC
and selected other cancers trials.
To address these concerns, a consortium of drug man-
ufacturers and representatives from Dako and Ventana,
organized in part through a joint effort of the FDA,
Table 3 Response rates to anti-PD-1/PD-L1 antibodies in NSCLC and selected malignancies according to PD-L1 positivity (Continued)
TC or IC 1–49 % 57 19
TC and IC <1 % 60 13
Durvalumab (MEDI4736)
Rizvi et al. [68] SP263 NSCLC ≥25 % 84 27
<25 % 92 5
Segal et al. [69] SP263 HNSCC ≥25 % 22 18
<25 % 37 8
Avelumab (MSB0010718C)
Gulley et al. [70] ? NSCLC ≥5 % 122 15
<5 % 20 10
Apolo et al. [71] ? Urothelial ≥5 % 10 40
<5 % 22 9
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AACR, ASCO, and the International Association for the
Study of Lung Cancer (IASLC), was formed with the
task of creating a resource to compare the performances
of the four major PD-L1 companion assays. The ultimate
goal of this collaboration is to establish cross-platform
standards for PD-L1 positivity analogous to those for
ER, PR, and HER2 testing. Results of the pilot phase of
this “Blueprint project” were presented at the AACR An-
nual Meeting in 2016, and included 39 lung cases
reviewed by 3 pathologists [36]. Tumor cell PD-L1 stain-
ing was similar for the Ventana SP263 and two Dako as-
says, with less tumor staining by the Ventana SP142
assay. Interobserver variability was high when quantify-
ing immune cell positivity but not tumor cell positivity.
The performance of these assays (using their respective
PD-L1 staining thresholds) varied substantially, with the
Ventana SP142 assay labeling the highest number of sam-
ples as positive (79 %) and the Ventana SP263 labeling the
fewest as positive (53 %). Both Dako assays (28–8 and
22C3) performed nearly identically with an intermediate
rate of positivity, and there was incomplete overlap between
all of the assays. These important preliminary observations
highlight the potential for false positive and negative results
based solely on the assay chosen. Additional predictive in-
formation, larger sample sizes, and potentially adjustments
to the cutoffs will be required before any conclusions can
be made about the merits of each assay.
Additional challenges to biomarker development
There are other biological limitations to PD-L1 detection in
tumor biopsies. Most traditional cancer biomarkers evalu-
ate fixed elements that do not vary tremendously with time
such as gene mutations or proteins directly involved in cel-
lular growth signaling or replication. Examples include es-
trogen and progesterone receptor expression, HER2 gene
amplification, or mutations in EGFR, KRAS, etc. Alterna-
tively, the PD-L1 gene is not typically mutated or amplified
and its expression is dynamic both in space and over time
in response to a constantly evolving immune response.
There is concern that sampling error could result in false
negative tests, though some recent case series have sug-
gested a reasonable concordance between both synchron-
ous (same time but different location) and metachronous
(different time) specimen in the range of 75–90 % [37–40].
PD-L1 expression is also affected by concurrent or prior
treatments, including radiation or chemotherapy, which
may have been administered after a biopsy was obtained
[41–44].
Alternative biomarker approaches have focused on
quantifying and qualifying tumor infiltrating lympho-
cytes (TILs) or on identifying tumor neoantigens, which
are fragments of mutated proteins displayed in the major
histocompatibility complexes (MHC) of tumor cells and
which are probably critical to the anti-tumor immune
response. Several studies now have found that the muta-
tional load, as well as the number of predicted neoanti-
gens (according to computerized algorithms which
account for MHC binding), are better predictors of re-
sponse to checkpoint inhibition than PD-L1 IHC, TILs,
or clinical variables [45–47]. While efforts are underway
to better understand and identify these neoantigens
through exome sequencing, surrogate measures of the
mutation burden such as chronic carcinogen exposure
(eg. tobacco, ultraviolet light) and defects in DNA repair
mechanisms (microsatellite instability/mismatch repair
defects, BRCA and POLE mutations) have emerged as
clinically useful biomarkers [46–48].
Conclusions
The recent FDA approvals of nivolumab and pembroli-
zumab represent the earliest phase of a major paradigm
shift in treating NSCLC. So far, it appears that both anti-
PD-1 antibodies, as well as the therapeutic anti-PD-L1
antibodies in development, will have comparable efficacy
and toxicity, with responses in approximately 15–20 %
of unselected NSCLC patients and serious autoimmune
toxicities in 5–10 % of patients. In the absence of head-
to-head to comparisons or clear biological differences
between these agents, it is not possible to recommend
one treatment over another.
Due to the low toxicity of checkpoint inhibitors and the
theorized synergy with other treatment modalities [49, 50],
combination clinical trials of anti-PD-1 antibodies with
chemotherapy, radiation, and other immunotherapies are
ongoing in the metastatic setting. The most mature of these
have combined anti-PD-1 or anti-PD-L1 antibodies with
anti-CTLA-4 antibodies with impressive results at the cost
of increased toxicity [51–54]. This strategy has been effect-
ive in the treatment of melanoma. It also remains to be
proven that these agents are as effective in the first-line set-
ting, though in the treatment naive cohort in KEYNOTE
001 pembrolizumab appeared equally efficacious and rates
of PD-L1 positivity were comparable to previously treated
patients (~23 % with PD-L1 PS ≥50 % in either group).
In the current clinical realm of FDA-approved immuno-
therapies, the role of PD-L1 testing is largely prognostic
for patients beginning treatment with either nivolumab or
pembrolizumab given that none of the assays can conclu-
sively identify non-benefiting patients. In light of the pre-
liminary results from Blueprint, it is not possible to
recommend one assay over another. From a practical
standpoint some clinicians may choose the 22C3-based
assay to have optional access to pembrolizumab in the
event of a positive assay. Meanwhile many laboratories
have begun reporting both tumor and immune cell posi-
tivity analogous to the atezolizumab companion assay by
Ventana, however the meaning of these separate scores is
still very much uncertain. As more treatment options and
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combinations become available, measures of immune acti-
vation including PD-L1 expression will clearly become
more relevant, particularly as the clinician factors the line
of therapy and weighs the potential benefit and toxicity of
combination immunotherapy in PD-L1 positive versus
negative tumors. Specifically, it remains to be shown
whether PD-L1 negative patients should be treated con-
currently with an anti-CTLA-4 antibody (such as ipilimu-
mab or tremelimumab) as appears to be the evolving
strategy for melanoma. It seems PD-L1 expression repre-
sents one lens and sensitivity and specificity is likely to be
more robust as multiple lenses are used in the analyses.
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